Nurix Therapeutics appoints Roger Dansey to board of directors

Nurix Therapeutics Inc. (NASDAQ: NRIX) announced the appointment of Roger Dansey, M.D., to its board of directors. Dansey previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc.

Dansey served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology from January 2024 until his retirement in March 2025. He was President of Research and Development at Seagen from November 2022 until Pfizer's acquisition of Seagen in December 2023. Dansey served as interim Chief Executive Officer of Seagen from May 2022 until November 2022 and was Chief Medical Officer at Seagen from May 2018 until May 2022.

Earlier in his career, Dansey held senior positions at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda across multiple tumor types, and served as Vice President of Oncology Clinical Research at Gilead Sciences. He was also the Global Development Lead for Xgeva at Amgen and worked as an associate professor of hematology and oncology at the Karmanos Cancer Institute in Detroit.

Dansey currently serves on the boards of directors of Bicycle Therapeutics plc, Inovio Pharmaceuticals Inc., MycRX Pharma, Ottimo Pharma Ltd and Shasqi Inc. He holds an M.D. from the University of Witwatersrand in Johannesburg, South Africa.

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for oncology and autoimmune diseases. The company is conducting pivotal trials for its lead asset, bexobrutideg, in chronic lymphocytic leukemia.

You May Also Be Interested In

• Standard Nuclear names former DOE nuclear policy chief to its board
• Exzeo Group authorizes $25 million share repurchase program
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027